New data from a late-stage trial showed that 78 percent of patients treated with Lemtrada remained relapse-free for two years, compared with 59 percent using Rebif, an older multiple sclerosis drug sold by Germany's Merck.
Lemtrada is a key experimental product at Sanofi's Genzyme unit. The fortunes of the drug are closely watched by holders of Genzyme Contingent Value Rights certificates issued to shareholders as part of the U.S. company's takeover deal.
CVRs represent an extra fee holders will receive if Lemtrada hits certain targets or when Genzyme meets other milestones.
The commercial potential of the drug, already sold under the brand name Campath as a leukemia treatment, was a key bone of contention between Sanofi and Genzyme during takeover talks.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1307